Guidepoint Qsight

From Today’s Patient Spend to Tomorrow’s Energy-Based Device Market Leaders Qsight’s patient sales data shows exactly where patients are spending now across the EBD market. Skin rejuvenation leads at over 60% of spend, with body contouring, hair removal, and skin tightening dividing the rest. But for aesthetic manufacturers and investors, the real question is: where will patients spend next? That’s where Qsight delivers more than a snapshot. Our data uncovers shifts in patient demand, changing category share, and evolving treatment priorities—insights you need to know before the competition does. In a market this competitive, knowing where to invest next isn’t optional. It’s the difference between remaining a leader—or becoming one. 👉 Contact us to see where the EBD market is headed. https://lnkd.in/dsCwhsVm #MedicalAesthetics #EnergyBasedDevices #QsightData #PatientTrends #AestheticInvesting

Meet Andrew Mantis, General Manager of Guidepoint Qsight. Andy’s spent the last 25+ years of his career building strategies, creating new revenue streams, and turning data into meaningful growth. From American Express and MasterCard to NPD, 1010data, and Commerce Signals, he’s helped brands, retailers, and financial institutions understand their markets more clearly—and act on the opportunities that matter. What sets Andy apart isn’t just the depth of his experience, but his knack for spotting what’s next. Whether it’s guiding teams to think differently or bringing new ideas to market, he’s always been focused on impact. “Across industries, I’ve seen how powerful it is when data stops being numbers on a page and starts guiding decisions. At Qsight, we get to do that every day for key segments in healthcare, from medical devices to aesthetics — helping leaders move with more confidence and clarity.” — Andy Mantis Today, Andy manages business functions at Qsight as it continues to be one the most trusted sources for healthcare market intelligence.

Qsight data was just featured in Allure Magazine: “With Even More Powerful GLP-1s on the Horizon, Plastic Surgeons Are Upping the Body Contouring Game for Ozempic Patients.” According to Guidepoint Qsight, 60% of US med spas and 35% of aesthetic physician offices prescribe GLP-1 medications. 👉 Read the full article here: https://lnkd.in/gbeyWKNB

Gen Z is shaping the future of aesthetics.   Qsight data reveals that in 2017, Gen Z accounted for just 4% of all aesthetics patients. By 2024, their share has more than doubled to 10%.   This growth reflects not only a demographic aging into eligibility but also early adoption across non-surgical categories, from neurotoxins to professional-grade skincare. As Gen Z continues to drive new patterns of engagement, their preferences and behaviors will shape the aesthetics landscape for years to come.   At Qsight, we track these shifts in real time, helping industry leaders understand where demand is headed next.   #Aesthetics #GenZ #HealthcareData #Qsight

Poll Results Are In! Last week, we asked: Which aesthetic category is seeing the biggest sales growth in 2025? Here’s what the data shows ⬇️ Winner: Non-EBD (non-energy-based device) Skin Rejuvenation +10% YoY growth in Q2 2025 ~$380M in patient spending at U.S. medical aesthetics practices Growth was fueled primarily by mechanical microneedling procedures, according to Qsight transaction data. Runner-up: Biostimulatory Injectable Dermal Fillers +8% YoY growth This category continues its strong momentum and remains a major driver of growth in aesthetics. What does this mean? Consumers are increasingly drawn to treatments that are minimally invasive, effective, and preventive—a trend shaping the next era of aesthetics.

Supplements are surging in aesthetics. Qsight was recently featured in MedEsthetics highlighting the rapid growth of the nutraceutical market. With consumer interest accelerating and strong category momentum, supplements are becoming an increasingly important part of the aesthetics conversation. 📖 Read more in MedEsthetics: With Supplement Sales Soaring, Providers Face New Responsibilities in the Expanding Nutraceutical Market https://lnkd.in/eF7HW9ZM

Aesthetics isn’t just about “turning back the clock” anymore. Gen Z is rewriting the playbook, entering aesthetics earlier, not to correct, but to prevent. Instead of waiting for wrinkles or skin damage to show up, this generation is embracing “prejuvenation” using neurotoxins, skin resurfacing, and advanced skincare as part of their wellness routine. And the data is striking: Neurotoxin treatments now make up 20% of Gen Z’s spend, nearly doubling since 2021. What does this mean? Aesthetics is shifting from restoration to prevention—and it’s transforming how clinics, providers, and brands should engage with the next wave of consumers. Dive into our latest blog where we unpack the generational shift toward preventive aesthetics and what it means for the future of the industry: https://lnkd.in/e57F_Zei

Survey data reveals what’s next. POS data validates what’s real.   At Qsight, we integrate both: POS Data shows verified transactions, patient spend, and product usage — objective measures of what has already happened. Survey Data captures sentiment, intent, and forward-looking perspectives from physicians, practices, and consumers   Together, they provide a 360° view of the aesthetics market, enabling manufacturers, and investors to anticipate change with confidence and act on insights that are both predictive and validated.   #MedicalAesthetics #MarketIntelligence #DataDrivenInsights #Qsight

The aesthetics industry is evolving fast in 2025 — but which category is seeing the biggest sales growth so far this year? We’ve narrowed it down to three top contenders: Biostimulatory Injectables Neurotoxins Skin Rejuvenation & Resurfacing (EBD) Cast your vote below 👇 — and let’s see which treatment is leading the way in H1 2025. (We’ll share the actual market data soon) #Aesthetics #MedicalAesthetics #MarketTrends #Injectables #SkinRejuvenation

The Qsight team will be at the Science of Skin Summit! We look forward to connecting with industry leaders to discuss go-to-market strategy, share our latest offerings, and highlight how Qsight’s data solutions support informed decision-making. Our team, Erik Haines, Managing Director, and Howard Koval, SVP of Sales, will be on site and available for meetings. Please reach out to schedule a time or simply come say hello during the Summit. 🔗 qsight.guidepoint.com 📍 September 5-7 in Austin, TX #ScienceofSkinSummit #MedicalAesthetics #StrategicInsights #Qsight #SSS2025